Kelix Bio, a specialty generics company focused on emerging markets, has announced a deal to acquire Chemi Pharma’s injectable oncology manufacturing business in Malta, as part of efforts to “further enhance Kelix Bio’s strategy of improving access to oncology therapies across global emerging markets.”
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?